New drug duo takes on stubborn leukemia

NCT ID NCT03534323

First seen Mar 29, 2026 · Last updated Apr 28, 2026 · Updated 4 times

Summary

This study tests a new drug (duvelisib) combined with an approved drug (venetoclax) in 55 adults whose chronic lymphocytic leukemia (CLL) or Richter's syndrome has come back or not responded to prior treatment. The goal is to see how well the combination shrinks or controls the cancer. Participants must have tried at least one prior therapy (except for Richter's syndrome).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Berkshire Medical Center

    Pittsfield, Massachusetts, 01201, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Northern Light Eastern Maine Medical Center

    Brewer, Maine, 04412, United States

  • University of Miami- Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.